The role of the complement factor B-arginase-polyamine molecular axis in uremia-induced cardiac remodeling in mice

Yang Yang1, Lu Ma1, Minghui Song1

  • 1Kidney Therapeutic Center of the Chinese People's Liberation Army, Beidaihe Rehabilitation and Recuperation Center of the Chinese People's Liberation Army, Qinhuangdao, China.

Insights

Complement factor B (CFB) exacerbates cardiac remodeling in uremia by upregulating arginase 1 (ARG1) in macrophages, leading to polyamine overproduction. Targeting this axis offers a potential therapy for uremic heart disease.

Area of Science:

  • Cardiovascular Research
  • Renal Medicine
  • Immunology

Background:

  • The role of the complement system in heart disease remains debated.
  • Mechanisms linking complement to cardiac remodeling and heart failure in uremia are poorly understood.

Purpose of the Study:

  • To investigate the role of complement factor B (CFB) in uremia-induced cardiac remodeling.
  • To elucidate the underlying mechanisms involving macrophages and polyamine synthesis.

Main Methods:

  • Established a uremic mouse model via 5/6 nephrectomy.
  • Assessed cardiac remodeling, complement component levels, and macrophage activity.
  • Utilized in vivo and in vitro experiments to study the CFB-arginase 1 (ARG1) pathway.
  • Administered ARG1 inhibitors and liposomal clodronate to deplete macrophages.

Main Results:

  • Uremia led to progressive cardiac remodeling and elevated soluble CFB levels.
  • CFB exacerbated cardiac remodeling, an effect reversed by macrophage depletion.
  • CFB upregulated ARG1 expression and activity in macrophages, promoting putrescine synthesis.
  • Putrescine stimulated cardiac fibroblast proliferation and collagen production.
  • ARG1 inhibition improved survival rates and alleviated cardiac remodeling in uremic mice.

Conclusions:

  • The CFB-ARG1-putrescine axis contributes to cardiac remodeling progression in uremia.
  • Hyperactivity of ARG1 in macrophages represents a potential therapeutic target for uremic heart injury.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
852
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
624
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K